Skip to main content

Toxicity Induced by he Chemical Carcinogen 7,12-Dimethylbenz[a]anthracene and the Protective Effects of Selenium in Wistar Rats

Buy Article:

$71.00 + tax (Refund Policy)

7,12-Dimethylbenz[a]anthracene (DMBA), a polycyclic aromatic hydrocarbon (PAH), has been used extensively as a tool to initiate mammary carcinogenesis and subsequent chemoprevention. On the other hand, selenium (Se) is potentially useful in oncology because this element possesses anticarcinogenic and chemopreventive properties. Se-containing enzymes such as glutathione peroxidase (GPx) play an important role in PAH metabolism and detoxification. In this study, rats were administered a single, oral dose of DMBA (12 mg). In the Se group, rats received 20 µg Se daily via gavage, starting 2 wk before the DMBA administration and continued for 1 wk. One hundred twenty days after DMBA administration the rats were sacrificed and toxicity was evaluated using histopathological and biochemical criteria. Five rats (30%) died in the DMBA group within the study period, whereas no death occurred in the DMBA–Se-treated group. Malignant tumor frequency was 33% in the DMBA group, while no malignant tumors occurred in the DMBA–Se-treated group. Some inflammatory changes rather than epithelial changes were found upon histopathological examination. GPx activity and blood urea nitrogen levels were higher and kidney GST activity was lower in the DMBA–Se-treated group compared to DMBA alone. In conclusion, Se appears to be effective in preventing some of the adverse effects associated with DMBA.

Document Type: Research Article

Affiliations: 1: Institute of Oncology, Dokuz Eylul University 2: Department of Surgery, Dokuz Eylul University Medical Faculty 3: Department of Pathology, Dokuz Eylul University Medical Faculty 4: Multidiscipline Laboratory, Dokuz Eylul University 5: Department of Medical Oncology, Dokuz Eylul University Medical Faculty 6: ARLAB, Dokuz Eylul University, Inciralti, Izmir, Turkey

Publication date: 01 May 2005

More about this publication?
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content